Whitney Espinel

The Impact of Chatbot Type and Normative Messaging on Chatbot Usage Intention Based on the Health Technology Acceptance Model: Randomized Controlled Trial

Yi Liao, Anne C. Madeo, Caitlin G. Allen, Melissa Kristen Frey et autres

Abstract Background Digital health tools, such as health chatbots, may improve access to scalable health support, but adoption remains inconsistent. Existing models do not fully integrate technology acceptance factors with health motivation factors relevant to digital health use. Objective This study proposed …

us (code pays fourni par la source)

Understanding usage intention and behavior for a health chatbot: An integrated model applied to non-Latino, English-preferring Latino, and Spanish-preferring Latino populations

Yi Liao, Anne C. Madeo, Caitlin G. Allen, Melissa Frey et autres

This study examined factors influencing intentions to use and actual usage of a genetics education chatbot among non-Latino, English-preferring Latino, and Spanish-preferring Latino populations using an integrated Theory of Planned Behavior (TPB) and Health Belief Model (HBM) framework. This integration captures both …

us (code pays fourni par la source)

Supplemental Figure S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial

Leigha Senter, Shelly Renee Anstey Hovick, Rachel Notestine, Lauren Norden et autres

Supplemental Figure S1: Enhanced Risk Estimate Participant Reports.

Supplemental Materials S2 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial

Leigha Senter, Shelly Renee Anstey Hovick, Rachel Notestine, Lauren Norden et autres

Supplemental Materials S2. Survey Scoring.

Supplemental Table S5 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial

Leigha Senter, Shelly Renee Anstey Hovick, Rachel Notestine, Lauren Norden et autres

Supplemental Table S5. Representativeness of Study Participants.

Supplemental Table S2 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial

Leigha Senter, Shelly Renee Anstey Hovick, Rachel Notestine, Lauren Norden et autres

Supplemental Table S2. SNVs and weights used for BRCA2 88-SNV Breast PRS model.

Supplemental Table S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial

Leigha Senter, Shelly Renee Anstey Hovick, Rachel Notestine, Lauren Norden et autres

Supplemental Table S1. SNVs and weights used for BRCA1 ER- 53-SNV Breast PRS Model.

Supplemental Materials S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial

Leigha Senter, Shelly Renee Anstey Hovick, Rachel Notestine, Lauren Norden et autres

Supplemental Materials S1. Baseline and Follow-up Survey Questions.

Supplemental Table S4 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial

Leigha Senter, Shelly Renee Anstey Hovick, Rachel Notestine, Lauren Norden et autres

Supplemental Table S4. SNVs and weights used for BRCA2 Ovarian PRS model.

Supplemental Table S6 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial

Leigha Senter, Shelly Renee Anstey Hovick, Rachel Notestine, Lauren Norden et autres

Supplemental Table S6. Comparison of GRE and 313-SNV breast cancer risks.

Supplemental Table S3 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial

Leigha Senter, Shelly Renee Anstey Hovick, Rachel Notestine, Lauren Norden et autres

Supplemental Table S3. SNVs and weights used for BRCA1 Ovarian PRS model.

Data from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial

Leigha Senter, Shelly Renee Anstey Hovick, Rachel Notestine, Lauren Norden et autres

Abstract Individuals with germline BRCA1 or BRCA2 pathogenic variants (PV) may struggle with risk management decision-making. Advancements in technology could provide more specific risk information to patients, but the impact of this information is unknown. The Clinical Application of Refined Risk Estimates …